Combined Astana city and Akmol village |
Prevalence of HC among all |
28.4% |
24.0–32.7 |
118/416 |
44.1% |
39.8–48.3 |
237/538 |
37.2% |
34.1–40.3 |
355/954 |
Awareness among all cases of HC |
47.5% |
38.3–56.6 |
56/118 |
61.2% |
54.9–67.4 |
145/237 |
56.6% |
51.4–61.8 |
201/355 |
Treatment among all cases of HC |
33.1% |
24.4–41.7 |
39/118 |
44.3% |
37.9–50.7 |
105/237 |
40.6% |
35.4–45.7 |
144/355 |
Treatment among aware |
67.9% |
55.2–80.5 |
38/56 |
71.7% |
64.3–79.1 |
104/145 |
70.7% |
64.3–77.0 |
142/201 |
Control among all cases of HC |
26.3% |
18.2–34.3 |
31/118 |
21.9% |
16.6–27.2 |
52/237 |
23.4% |
19.0–27.8 |
83/355 |
Control among treated |
79.5% |
66.2–92.7 |
31/39 |
49.5% |
39.8–59.2 |
52/105 |
57.6% |
49.5–65.8 |
83/144 |
Astana city (urban, n = 480) |
Prevalence of HC among all |
38.2% |
31.7–44.7 |
84/220 |
57.3% |
51.3–63.4 |
149/260 |
48.5% |
44.1–53.0 |
233/480 |
Awareness among all cases of HC |
56.0% |
45.1–66.8 |
47/84 |
72.5% |
65.2–79.7 |
108/149 |
66.5% |
60.4–72.6 |
155/233 |
Treatment among all cases of HC |
36.9% |
26.4–47.4 |
31/84 |
49.7% |
41.5–57.8 |
74/149 |
45.1% |
38.6–51.5 |
105/233 |
Treatment among aware |
63.8% |
49.6–78.1 |
30/47 |
68.5% |
59.6–77.4 |
74/108 |
67.1% |
59.6–74.6 |
104/155 |
Control among all cases of HC |
29.8% |
19.8–39.7 |
25/84 |
24.8% |
17.8–31.9 |
37/149 |
26.6% |
20.9–32.3 |
62/233 |
Control among treated |
80.7% |
65.9–95.4 |
25/31 |
50.0% |
38.3–61.7 |
37/74 |
59.1% |
49.5–68.6 |
62/105 |
Akmol village (rural, n = 474) |
Prevalence of HC among all |
17.4% |
12.0–22.7 |
34/196 |
31.7% |
26.2–37.2 |
88/278 |
25.7% |
21.8–29.7 |
122/474 |
Awareness among all cases of HC |
26.5% |
10.8–42.1 |
9/34 |
42.1% |
31.5–52.6 |
37/88 |
37.7% |
29.0–46.4 |
46/122 |
Treatment among all cases of HC |
23.5% |
8.5–38.6 |
8/34 |
35.2% |
25.0–45.4 |
31/88 |
32.0% |
23.6–40.4 |
39/122 |
Treatment among aware |
88.9% |
63.3–114.5 |
8/9 |
81.1% |
67.8–94.3 |
30/37 |
82.6% |
71.2–94.0 |
38/46 |
Control among all cases of HC |
17.7% |
4.1–31.1 |
6/34 |
17.1% |
9.0–25.1 |
15/88 |
17.2% |
10.4–24.0 |
21/122 |
Control among treated |
75.0% |
36.3–113.7 |
6/8 |
48.4% |
29.8–67.0 |
15/31 |
53.9% |
37.5–70.2 |
21/39 |